Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 4,117 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
Interventions: TTHX1114(NM141), Vehicle (placebo); Drug · Other
Lead sponsor: Trefoil Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Petaluma, California • Jacksonville, Florida • Hoffman Estates, Illinois + 5 more

Conditions: Meningococcal Disease
Interventions: MenABCWY+OMV, MenABCWY+¼OMV, Placebo; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: Birmingham, Alabama • Madera, California • Paramount, California + 5 more

Conditions: Isolated Systolic Hypertension, Endothelial Dysfunction
Interventions: 6R-BH4, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Abdominoplasty
Interventions: Genius, eC02, PicoPlus, LaseMD, LaseMD Flex; Device
Lead sponsor: CynosureLutronic; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Billerica, Massachusetts

Conditions: Obesity or Overweight
Interventions: AZD6234, Placebo comparator; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 23
States / cities: Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 19 more

Conditions: B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, HIV Associated Lymphoma, CNS Lymphoma, High-grade B-cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions: EB103; Biological
Lead sponsor: Estrella Immunopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Sacramento, California • Cleveland, Ohio • Portland, Oregon + 2 more

Conditions: Hypertension
Interventions: Azilsartan Medoxomil Low-dose, Losartan, Placebo for Azilsartan Medoxomil, Placebo for Losartan, Azilsartan Medoxomil Medium-dose (20 mg), Azilsartan Medoxomil High-dose (40 mg); Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 17
States / cities: Anaheim, California • Hialeah, Florida • Miami, Florida + 12 more

Conditions: Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma
Interventions: 64Cu-LNTH-1363S; Combination Product
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 15 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Duarte, California • Orange, California • Stanford, California + 2 more

Conditions: Colorectal Carcinoma, Familial Adenomatous Polyposis
Interventions: Biopsy Procedure, Biospecimen Collection, EP2/EP4 Antagonist TPST-1495, Esophagogastroduodenoscopy, Gastrointestinal Endoscopy, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Phoenix, Arizona • Rochester, Minnesota • Salt Lake City, Utah + 1 more

Conditions: Hepatocellular Carcinoma, Cancer of Liver
Interventions: PXS-5505 and Atezolizumab and Bevacizumab; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Chronic Pain Patients, Medical Cannabis Users
Interventions: Cognitive testing, Task-based fMRI measure of face-name and verbal learning; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 30 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Friedreich Ataxia 1
Interventions: Nicotinamide Riboside, Placebo, Exercise Intervention; Dietary Supplement · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 10 Years to 40 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Plaque Psoriasis
Interventions: 188-0551 Spray, RLD; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Scottsdale, Arizona • Thousand Oaks, California • Miami, Florida

Conditions: Type 2 Diabetes
Interventions: Time restricted feeding; Behavioral
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Colorectal Cancer
Interventions: LYL273; Drug
Lead sponsor: Lyell Immunopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 5
States / cities: Duarte, California • San Francisco, California • Aurora, Colorado + 2 more

Conditions: Dry Eye
Interventions: Vehicle, SDP-4 Ophthalmic Solution (1.0%); Drug
Lead sponsor: Silk Technologies, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Garden Grove, California • Murrieta, California • Newport Beach, California + 2 more

Conditions: Smoking Cessation
Interventions: varenicline, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Austin, Texas • San Antonio, Texas

Conditions: Aging
Interventions: Mobile Service Robot, Survey; Device · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Venous Thromboembolism, Arterial Thromboembolism
Interventions: IMPROVE DD VTE Tool; Other
Lead sponsor: Northwell Health; Other
Eligibility: 60 Years and older
Enrollment: 10,699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Manhasset, New York • New Hyde Park, New York • New York, New York + 1 more

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Sintilimab, Cisplatin, Paclitaxel, Fluorouracil, Placebo; Biological · Drug
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 7
States / cities: Anaheim, California • Orange, California • Denver, Colorado + 4 more

Conditions: Hypertension
Interventions: Partial sleep deprivation (sleep restriction), Normal sleep; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 35 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cancer
Interventions: EC0489, Injection, EC20; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 6
States / cities: Lafayette, Indiana • Baltimore, Maryland • Bethesda, Maryland + 3 more

Conditions: Low Back Pain
Interventions: Experimental Intervention, Placebo Comparator; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions: BIBW 2992, Cetuximab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 18
States / cities: Stanford, California • Chicago, Illinois • Harvey, Illinois + 14 more

Search by objective public record fields.

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction

Histologic Evaluation of Tissue Following Lutronic System Exposure

A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

Medical Cannabis and Behavior

NAD+ and Exercise in FA

A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis

Application of Time Restriction Feeding in Patients With Type 2 Diabetes Mellitus

LYL273 for Patients With Relapsed or Refractory mCRC

Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)

Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo

Affordable Mobile Robots for the Elderly

A Universal Electronic Health Record-based IMPROVE DD VTE Risk Assessment Model for the Prevention of Thromboembolism in Hospitalized Medically Ill Patients

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Sleep Restriction and Parental History of Hypertension

Study of EC0489 for the Treatment of Refractory or Metastatic Tumors

Worksite Exercise Interventions for Low Back Injury Prevention in Firefighters

BIBW 2992 (Afatinib) in Head & Neck Cancer